Gilead Sciences (GILD) EBITDA Margin: History & Chart

Gilead Sciences, Inc.(GILD)

Drug Manufacturers - General · Foster City, CA

$145.65+0.00 (+0.00%)

Delayed quote: Sep 9, 2026, 4:00 PM EDT

About Gilead Sciences, Inc.

Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to address critical health needs. The company's extensive product portfolio encompasses treatments for a variety of severe conditions. For HIV/AIDS, it supplies key therapies such as Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. In response to the 2019 coronavirus pandemic, Gilead provides Veklury, an injectable drug for intravenous administration. Its offerings for liver diseases include Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. Furthermore, Gilead assists patients battling hematological disorders, various cancers, and those undergoing cell therapy, through products like Yescarta, Tecartus, Trodelvy, and Zydelig. Other specialized medicines include Letairis, an oral drug for pulmonary arterial hypertension; Ranexa, also an oral medication, for chronic angina; and AmBisome, a liposomal formulation designed to combat serious invasive fungal infections. Gilead Sciences, Inc. actively engages in collaboration agreements with a diverse range of partners to advance its therapeutic pipeline. These include Arcus Biosciences, Inc., Pionyr Immunotherapeutics Inc., Tizona Therapeutics, Inc., Tango Therapeutics, Inc., Jounce Therapeutics, Inc., Galapagos NV, Janssen Sciences Ireland Unlimited Company, Japan Tobacco, Inc., Gadeta B.V., Bristol-Myers Squibb Company, Dragonfly Therapeutics, Inc., and Merck & Co, Inc. The company was founded in 1987 and its corporate headquarters are situated in Foster City, California.

Foster City, CA

17,000 employees

www.gilead.com

Healthcare / Drug Manufacturers - General

Sector: Healthcare
Industry: Drug Manufacturers - General
CEO: Daniel O'Day

View full financials

GILD EBITDA Margin Metrics

EBITDA MARGIN

49.12%

EBITDA MARGIN AVG TTM

11.32%

EBITDA MARGIN AVG 3Y

41.73%

EBITDA MARGIN AVG 5Y

39.84%

EBITDA MARGIN AVG 10Y

45.59%

EBITDA MARGIN AVG 15Y

49.06%

EBITDA MARGIN AVG 20Y

50.79%

CURRENT VS TTM AVG

+334.09%

CURRENT VS 3Y AVG

+17.71%

CURRENT VS 5Y AVG

+23.30%

CURRENT VS 10Y AVG

+7.74%

CURRENT VS 15Y AVG

+0.11%

CURRENT VS 20Y AVG

-3.28%

NAME	MARKET CAP	EBITDA MARGIN	TTM	3Y	5Y
Gilead Sciences, Inc. (GILD)	$180.83B	49.12%	11.32%	41.73%	39.84%
Abbott Laboratories (ABT)vs ›	$182.12B	24.35%	24.15%	24.77%	25.59%
Novo Nordisk A/S (NVO)vs ›	$197.87B	48.42%	49.59%	48.46%	47.82%
Pfizer Inc. (PFE)vs ›	$158.33B	32.51%	34.72%	32.84%	32.73%
Amgen Inc. (AMGN)vs ›	$211.17B	43.12%	40.78%	43.34%	44.32%
Danaher Corporation (DHR)vs ›	$144.11B	30.87%	31.21%	32.47%	31.98%
Thermo Fisher Scientific Inc. (TMO)vs ›	$225.09B	24.44%	24.78%	25.35%	27.67%
Vertex Pharmaceuticals Incorporated (VRTX)vs ›	$132.26B	41.14%	20.45%	32.86%	36.27%
Bristol-Myers Squibb Company (BMY)vs ›	$131.57B	36.80%	38.33%	39.88%	39.69%
Intuitive Surgical, Inc. (ISRG)vs ›	$124.79B	35.99%	34.83%	32.83%	33.22%

NAME

MARKET CAP

EBITDA MARGIN

TTM

Gilead Sciences, Inc. (GILD)

$180.83B

49.12%

11.32%

41.73%

39.84%

Abbott Laboratories (ABT)vs ›

$182.12B

24.35%

24.15%

24.77%

25.59%

Novo Nordisk A/S (NVO)vs ›

$197.87B

48.42%

49.59%

48.46%

47.82%

Pfizer Inc. (PFE)vs ›

$158.33B

32.51%

34.72%

32.84%

32.73%

Amgen Inc. (AMGN)vs ›

$211.17B

43.12%

40.78%

43.34%

44.32%

Danaher Corporation (DHR)vs ›

$144.11B

30.87%

31.21%

32.47%

31.98%

Thermo Fisher Scientific Inc. (TMO)vs ›

$225.09B

24.44%

24.78%

25.35%

27.67%

Vertex Pharmaceuticals Incorporated (VRTX)vs ›

$132.26B

41.14%

20.45%

32.86%

36.27%

Bristol-Myers Squibb Company (BMY)vs ›

$131.57B

36.80%

38.33%

39.88%

39.69%

Intuitive Surgical, Inc. (ISRG)vs ›

$124.79B

35.99%

34.83%

32.83%

33.22%

EBITDA Margin FAQ

What is the EBITDA margin for Gilead Sciences, Inc. (GILD)?

The EBITDA margin for GILD stock is 49.12%.

Is Gilead Sciences, Inc.'s EBITDA margin high or low?

The EBITDA margin of 49.12% is 23% above its 5-year average of 39.84%, near the high end of its 5-year range (-133.21%–58.82%).

What is the TTM average EBITDA margin for Gilead Sciences, Inc. (GILD)?

The TTM average EBITDA margin for GILD stock is 11.32%.

What is the 3Y average EBITDA margin for Gilead Sciences, Inc. (GILD)?

The 3Y average EBITDA margin for GILD stock is 41.73%.

What is the 5Y average EBITDA margin for Gilead Sciences, Inc. (GILD)?

The 5Y average EBITDA margin for GILD stock is 39.84%.

What is the 10Y average EBITDA margin for Gilead Sciences, Inc. (GILD)?

The 10Y average EBITDA margin for GILD stock is 45.59%.

What is the 15Y average EBITDA margin for Gilead Sciences, Inc. (GILD)?

The 15Y average EBITDA margin for GILD stock is 49.06%.

What is the 20Y average EBITDA margin for Gilead Sciences, Inc. (GILD)?

The 20Y average EBITDA margin for GILD stock is 50.79%.

DATE	EBITDA MARGIN
2026-06-30	-133.21%
2026-03-31	47.05%
2025-12-31	46.38%
2025-09-30	51.65%
2025-06-30	44.70%
2025-03-31	43.99%
2024-12-31	41.55%
2024-09-30	20.91%
2024-06-30	48.01%
2024-03-31	-54.32%
2023-12-31	32.33%
2023-09-30	46.91%
2023-06-30	35.55%
2023-03-31	36.92%
2022-12-31	37.83%
2022-09-30	47.74%
2022-06-30	40.80%
2022-03-31	10.96%
2021-12-31	20.36%
2021-09-30	58.82%
2021-06-30	44.47%
2021-03-31	52.36%
2020-12-31	41.48%
2020-09-30	35.82%
2020-06-30	-51.22%
2020-03-31	49.59%
2019-12-31	24.54%
2019-09-30	-20.09%
2019-06-30	48.87%
2019-03-31	49.16%
2018-12-31	25.92%
2018-09-30	53.27%
2018-06-30	46.67%
2018-03-31	49.33%
2017-12-31	45.18%
2017-09-30	63.10%
2017-06-30	63.74%
2017-03-31	62.43%
2016-12-31	59.25%
2016-09-30	62.64%
2016-06-30	62.01%
2016-03-31	63.31%
2015-12-31	69.35%
2015-09-30	70.68%
2015-06-30	71.43%
2015-03-31	74.27%
2014-12-31	62.97%
2014-09-30	62.03%
2014-06-30	71.58%
2014-03-31	65.69%
2013-12-31	42.47%
2013-09-30	43.74%
2013-06-30	44.34%
2013-03-31	43.43%
2012-12-31	45.61%
2012-09-30	45.95%
2012-06-30	46.84%
2012-03-31	37.96%
2011-12-31	42.76%
2011-09-30	50.75%
2011-06-30	51.08%
2011-03-31	51.03%
2010-12-31	45.37%
2010-09-30	54.09%
2010-06-30	54.56%
2010-03-31	58.55%
2009-12-31	55.58%
2009-09-30	52.82%
2009-06-30	49.40%
2009-03-31	55.37%
2008-12-31	51.67%
2008-09-30	51.22%
2008-06-30	50.31%
2008-03-31	55.45%
2007-12-31	47.86%
2007-09-30	53.13%
2007-06-30	53.19%
2007-03-31	55.60%
2006-12-31	-171.42%
2006-09-30	9.25%
2006-06-30	55.14%
2006-03-31	55.26%
2005-12-31	61.37%
2005-09-30	52.61%
2005-06-30	57.33%
2005-03-31	53.35%
2004-12-31	46.46%
2004-09-30	52.08%
2004-06-30	51.36%
2004-03-31	48.61%
2003-12-31	35.72%
2003-09-30	42.08%
2003-06-30	47.19%
2003-03-31	-259.83%
2002-12-31	25.32%
2002-09-30	29.60%

DATE

EBITDA MARGIN

2026-06-30

-133.21%

2026-03-31

47.05%

2025-12-31

46.38%

2025-09-30

51.65%

2025-06-30

44.70%

2025-03-31

43.99%

2024-12-31

41.55%

2024-09-30

20.91%

2024-06-30

48.01%

2024-03-31

-54.32%

2023-12-31

32.33%

2023-09-30

46.91%

2023-06-30

35.55%

2023-03-31

36.92%

2022-12-31

37.83%

2022-09-30

47.74%

2022-06-30

40.80%

2022-03-31

10.96%

2021-12-31

20.36%

2021-09-30

58.82%

2021-06-30

44.47%

2021-03-31

52.36%

2020-12-31

41.48%

2020-09-30

35.82%

2020-06-30

-51.22%

2020-03-31

49.59%

2019-12-31

24.54%

2019-09-30

-20.09%

2019-06-30

48.87%

2019-03-31

49.16%

2018-12-31

25.92%

2018-09-30

53.27%

2018-06-30

46.67%

2018-03-31

49.33%

2017-12-31

45.18%

2017-09-30

63.10%

2017-06-30

63.74%

2017-03-31

62.43%

2016-12-31

59.25%

2016-09-30

62.64%

2016-06-30

62.01%

2016-03-31

63.31%

2015-12-31

69.35%

2015-09-30

70.68%

2015-06-30

71.43%

2015-03-31

74.27%

2014-12-31

62.97%

2014-09-30

62.03%

2014-06-30

71.58%

2014-03-31

65.69%

2013-12-31

42.47%

2013-09-30

43.74%

2013-06-30

44.34%

2013-03-31

43.43%

2012-12-31

45.61%

2012-09-30

45.95%

2012-06-30

46.84%

2012-03-31

37.96%

2011-12-31

42.76%

2011-09-30

50.75%

2011-06-30

51.08%

2011-03-31

51.03%

2010-12-31

45.37%

2010-09-30

54.09%

2010-06-30

54.56%

2010-03-31

58.55%

2009-12-31

55.58%

2009-09-30

52.82%

2009-06-30

49.40%

2009-03-31

55.37%

2008-12-31

51.67%

2008-09-30

51.22%

2008-06-30

50.31%

2008-03-31

55.45%

2007-12-31

47.86%

2007-09-30

53.13%

2007-06-30

53.19%

2007-03-31

55.60%

2006-12-31

-171.42%

2006-09-30

9.25%

2006-06-30

55.14%

2006-03-31

55.26%

2005-12-31

61.37%

2005-09-30

52.61%

2005-06-30

57.33%

2005-03-31

53.35%

2004-12-31

46.46%

2004-09-30

52.08%

2004-06-30

51.36%

2004-03-31

48.61%

2003-12-31

35.72%

2003-09-30

42.08%

2003-06-30

47.19%

2003-03-31

-259.83%

2002-12-31

25.32%

2002-09-30

29.60%

EBITDA Margin: 49.12%

GILD EBITDA Margin

GILD Average EBITDA Margin Chart

GILD Current vs Average EBITDA Margin Chart

GILD EBITDA Margin Metrics

GILD Competitors' EBITDA Margin

Margin Comparison

EBITDA Margin Formula & Definition

EBITDA Margin FAQ

GILD EBITDA Margin History

Related Metrics